Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Meropenem
Drug ID BADD_D01393
Description Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.
Indications and Usage For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (excluding vancomycin-resistant isolates), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species; complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. Also for use in the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitidis.
Marketing Status approved; investigational
ATC Code J01DH02
DrugBank ID DB00760
KEGG ID D02222; D08185
MeSH ID D000077731
PubChem ID 441130
TTD Drug ID D0O5FY
NDC Product Code 81962-000; 68001-447; 55150-208; 0781-3098; 81962-001; 63323-508; 63323-507; 68083-147; 0409-1391; 70121-1453; 70594-076; 44567-400; 55150-207; 0409-1390; 0781-3000; 52946-0839; 68001-324; 44567-145; 68083-146; 0409-0222; 70121-1454; 72572-415; 72572-416; 38217-0020; 38217-0021; 68001-323; 68001-446; 70278-103; 0409-3412; 70278-104; 70594-075; 44567-401; 44567-146
UNII FV9J3JU8B1
Synonyms Meropenem | 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid | Merrem | Ronem | Penem | SM 7338 | SM-7338 | SM7338
Chemical Information
Molecular Formula C17H25N3O5S
CAS Registry Number 96036-03-2
SMILES CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mixed liver injury09.01.07.0150.000049%-
Treatment failure08.06.01.0170.000632%-
Liver injury09.01.07.022; 12.01.17.0120.000122%-
Hypertransaminasaemia09.01.02.0050.000073%-
Acute kidney injury20.01.03.0160.000753%
Drug-induced liver injury09.01.07.023; 12.03.01.0440.000243%-
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.000437%-
Autoimmune haemolytic anaemia01.06.01.004; 10.04.01.0050.000097%-
Candida infection11.03.03.021--
Activated partial thromboplastin time ratio fluctuation13.01.02.034---
Multiple organ dysfunction syndrome08.01.03.0570.000267%
Convulsive threshold lowered17.12.03.0230.000146%-
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.000122%-
Faeces pale07.01.03.0050.000049%-
Thrombocytopenia neonatal01.08.01.010; 18.04.03.0050.000073%-
Pulmonary renal syndrome10.04.04.017; 20.05.01.019; 22.01.01.0220.000049%-
Cross sensitivity reaction10.01.01.0360.000097%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.000326%-
Fixed eruption08.01.06.025; 10.01.01.037; 23.03.05.0080.000122%-
Haemoperitoneum07.07.02.007; 12.01.17.007; 24.07.02.065---
Hepatic cytolysis09.01.07.0360.000049%-
Myelosuppression01.03.03.0150.000073%-
Neonatal seizure17.12.03.038; 18.04.04.0190.000049%-
Skin weeping23.03.03.1010.000049%-
Therapy non-responder08.06.01.0630.000073%-
Vulvovaginal inflammation21.14.02.014---
The 10th Page    First    Pre   10    Total 10 Pages